Findings of Research Misconduct, 76491 [2012-31287]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 249 / Friday, December 28, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
tkelley on DSK3SPTVN1PROD with
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Shuang-Qing Zhang, Ph.D., Texas
Tech University Health Sciences Center:
Based on the report of an investigation
conducted by the Texas Tech University
Health Sciences Center (TTUHSC) and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Shuang-Qing Zhang, former
Postdoctoral Researcher, Department of
Pharmaceutical Sciences, TTUHSC,
engaged in research misconduct in
research supported by National Institute
of General Medical Sciences (NIGMS),
National Institutes of Health (NIH),
grant R01 GM069869.
ORI found that Respondent engaged
in research misconduct by the
falsification and fabrication of
plagiarized data that were included in
the publication: Zhang, S.Q. & Mehavr,
R. ‘‘Determination of dextramethylprednisolone conjugate with
glycine linker in rat plasma and liver by
high-performance liquid
chromatography and its application in
pharmacokinetics.’’ Biomed.
Chromatogr. 24(4):351–357, 2010
(hereafter the ‘‘BC 2010 article’’).
Specifically, ORI found that the
Respondent:
• Falsified Figures 2(c) and 3(c) of the
BC 2010 article by misrepresenting
HPLC data that he had plagiarized,
originally generated prior to the
Respondent’s arrival in the laboratory
by a former postdoctoral researcher; in
Figure 2(c), the Respondent claimed that
the HPLC chromatogram was of a
‘‘plasma sample obtained 12 h after
intravenous injection of DMP to rats at
a single dose of 5 mg/kg,’’ while the
actual chromatogram was of a
calibration test of 1 mg/ml of DMP added
to rat plasma, and similarly in Figure
3(c), the Respondent claimed that the
HPLC chromatogram was of a ‘‘liver
homogenate obtained 3 h after
intravenous dose of DMP at a dose of 5
mg/kg,’’ while the actual chromatogram
was of a calibration test of 2 mg/ml DMP
added to rat liver homogenate.
• Falsified and fabricated Figure 4 of
the BC 2010 article; in the top panel, the
Respondent reported the measurement
of DMP concentrations in plasma
VerDate Mar<15>2010
20:15 Dec 27, 2012
Jkt 229001
samples of three rats after a single
injection of 5 mg/kg DMP while the
actual data that he had plagiarized,
originally generated prior to the
Respondent’s arrival in the laboratory
by a former postdoctoral researcher, was
from a single rat. In the bottom panel,
the Respondent reported the
measurement of DMP concentrations in
liver samples obtained from three rats at
1, 30, 90, 180, 300, and 720 minutes
after a single injection of 5 mg/kg DMP,
requiring a total of 18 rats, while the
actual data that he had plagiarized,
originally generated prior to the
Respondent’s arrival in the laboratory
by a former postdoctoral researcher, was
from plasma samples from a single rat,
and the error bars for both panels were
fabricated.
Dr. Zhang has entered into a
Voluntary Settlement Agreement and
has voluntarily agreed:
(1) To have his research supervised
for a period of three (3) years;
Respondent voluntarily agrees that
within sixty (60) days of the effective
date of the Agreement, any institution
that submits an application for PHS
support for a research project on which
the Respondent’s participation is
proposed or that uses the Respondent in
any capacity on PHS supported
research, or that submits a report of
PHS-funded research in which the
Respondent is involved, must
concurrently submit a plan for
supervision of the Respondent’s
research to ORI for approval;
Respondent agrees that he will not
participate in any PHS-supported
research after sixty (60) days from the
effective date of the Agreement until an
appropriate supervision plan is
submitted to ORI; the supervision plan
must be designed to ensure the
scientific integrity of the Respondent’s
research contribution; and
(2) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of three (3)
years, beginning on December 4, 2012.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852,(240) 453–8800.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2012–31287 Filed 12–27–12; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
76491
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Martin Biosse-Duplan, D.D.S., Ph.D.,
Harvard School of Dental Medicine:
Based on the report of an investigation
conducted by the Harvard School of
Medicine (HSM) and Harvard School of
Dental Medicine (HSDM), the admission
of the Respondent, and additional
analysis conducted by ORI in its
oversight review, ORI found that Dr.
Martin Biosse-Duplan, former Research
Fellow, Department of Oral Medicine,
Infection, and Immunity, HSDM,
engaged in research misconduct in
research supported by National Institute
of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS), National
Institutes of Health (NIH), grant R01
AR054450.
ORI found that the Respondent
engaged in research misconduct
involving one (1) laboratory
presentation and two (2) published
abstracts:
• Boisse-Duplan, M., Stephens, S.,
Lai, F.P.L., Oelkers, M., Kitamura, D.,
Rottner, K., Horne, W., & Baron, R. ‘‘The
Association Between the Microtubule
Plus End Protein EB1 and Cortactin
Controls Podosomes and Bone
Resorption.’’ J Bone Min Res 26:Supl.1,
pS215.
• Boisse-Duplan, M., Stephens, S.,
Lai, F.P.L., Oelkers, M., Rottner, K.,
Horne, W., & Baron, R. ‘‘In Osteoclasts,
Dynamic Microtubules and their
Associated Protein EB1 Control
Podosomes and Bone Resorption
through Cortactin.’’ Bone 48:Suppl. 2,
pS97.
As a result of HSM’s and HSDM’s
investigation, the data were not
presented at the meetings and the
experiments reported in the abstracts
are being redone.
Specifically, ORI finds that
Respondent:
• Falsified Powerpoint slides and
spreadsheets for histomorphometric and
microCT results by using the values of
HS1 knockout (KO) mice and their
controls to represent the CathepsinK
cre-Cortactin KO mice and their
controls; Dr. Biosse-Duplan also
switched two sets of numbers between
the HS1 KO mice and their controls to
E:\FR\FM\28DEN1.SGM
28DEN1
]]>Agencies
[Federal Register Volume 77, Number 249 (Friday, December 28, 2012)]
[Notices]
[Page 76491]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-31287]
[[Page 76491]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Shuang-Qing Zhang, Ph.D., Texas Tech University Health Sciences
Center: Based on the report of an investigation conducted by the Texas
Tech University Health Sciences Center (TTUHSC) and additional analysis
conducted by ORI in its oversight review, ORI found that Dr. Shuang-
Qing Zhang, former Postdoctoral Researcher, Department of
Pharmaceutical Sciences, TTUHSC, engaged in research misconduct in
research supported by National Institute of General Medical Sciences
(NIGMS), National Institutes of Health (NIH), grant R01 GM069869.
ORI found that Respondent engaged in research misconduct by the
falsification and fabrication of plagiarized data that were included in
the publication: Zhang, S.Q. & Mehavr, R. ``Determination of dextra-
methylprednisolone conjugate with glycine linker in rat plasma and
liver by high-performance liquid chromatography and its application in
pharmacokinetics.'' Biomed. Chromatogr. 24(4):351-357, 2010 (hereafter
the ``BC 2010 article''). Specifically, ORI found that the Respondent:
Falsified Figures 2(c) and 3(c) of the BC 2010 article by
misrepresenting HPLC data that he had plagiarized, originally generated
prior to the Respondent's arrival in the laboratory by a former
postdoctoral researcher; in Figure 2(c), the Respondent claimed that
the HPLC chromatogram was of a ``plasma sample obtained 12 h after
intravenous injection of DMP to rats at a single dose of 5 mg/kg,''
while the actual chromatogram was of a calibration test of 1 [mu]g/ml
of DMP added to rat plasma, and similarly in Figure 3(c), the
Respondent claimed that the HPLC chromatogram was of a ``liver
homogenate obtained 3 h after intravenous dose of DMP at a dose of 5
mg/kg,'' while the actual chromatogram was of a calibration test of 2
[mu]g/ml DMP added to rat liver homogenate.
Falsified and fabricated Figure 4 of the BC 2010 article;
in the top panel, the Respondent reported the measurement of DMP
concentrations in plasma samples of three rats after a single injection
of 5 mg/kg DMP while the actual data that he had plagiarized,
originally generated prior to the Respondent's arrival in the
laboratory by a former postdoctoral researcher, was from a single rat.
In the bottom panel, the Respondent reported the measurement of DMP
concentrations in liver samples obtained from three rats at 1, 30, 90,
180, 300, and 720 minutes after a single injection of 5 mg/kg DMP,
requiring a total of 18 rats, while the actual data that he had
plagiarized, originally generated prior to the Respondent's arrival in
the laboratory by a former postdoctoral researcher, was from plasma
samples from a single rat, and the error bars for both panels were
fabricated.
Dr. Zhang has entered into a Voluntary Settlement Agreement and has
voluntarily agreed:
(1) To have his research supervised for a period of three (3)
years; Respondent voluntarily agrees that within sixty (60) days of the
effective date of the Agreement, any institution that submits an
application for PHS support for a research project on which the
Respondent's participation is proposed or that uses the Respondent in
any capacity on PHS supported research, or that submits a report of
PHS-funded research in which the Respondent is involved, must
concurrently submit a plan for supervision of the Respondent's research
to ORI for approval; Respondent agrees that he will not participate in
any PHS-supported research after sixty (60) days from the effective
date of the Agreement until an appropriate supervision plan is
submitted to ORI; the supervision plan must be designed to ensure the
scientific integrity of the Respondent's research contribution; and
(2) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of three (3) years, beginning on December 4,
2012.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852,(240)
453-8800.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2012-31287 Filed 12-27-12; 8:45 am]
BILLING CODE 4150-31-P
